What safety precautions apply when using Spravato (esketamine) for depression?
Spravato is given only in a certified medical setting under a REMS (Risk Evaluation and Mitigation Strategy) program, because of risks like sedation, dissociation, and increases in blood pressure. The core safety precautions are built around monitoring during and after dosing. [1][2]
Why do patients need monitoring after Spravato—and for how long?
After each Spravato dose, patients must be monitored until they are considered safe to leave the facility. A key precaution is that patients can become sedated and have impaired judgment, so they need observation and must not drive themselves after treatment. [1][2]
What should patients avoid before and after a Spravato session?
Patients are generally required to avoid driving and other hazardous activities after treatment because of sedation and impaired alertness. The REMS structure also includes safeguards around how the dose is administered and how patients are released from care after observation. [1][2]
What blood-pressure and cardiovascular precautions are required?
Esketamine can increase blood pressure, so it requires blood-pressure assessment and monitoring around dosing. Patients with certain cardiovascular conditions may need additional evaluation before treatment and closer monitoring during the REMS-controlled dosing process. [1][2]
Are there medication or substance interactions patients should know about?
Because sedation is a major safety concern, precautions include careful management of other medicines and substances that can also cause central nervous system depression. The REMS requirements and labeling warnings are designed to reduce the risk of excessive sedation and related events. [1][2]
What happens if a patient becomes overly sedated or has other adverse effects?
The REMS program anticipates that some patients may experience sedation, dissociation, or other acute effects around dosing. Facilities are required to have procedures and staffing to manage patients during the post-dose monitoring period until symptoms resolve to a safe level for discharge. [1][2]
Where can I find the formal REMS safety instructions for Spravato?
For the most up-to-date prescribing and REMS-related safety information (including monitoring and patient-release requirements), check the Spravato REMS program materials and the official prescribing information. DrugPatentWatch.com also tracks key regulatory and patent context for Spravato, which can help when researching the drug’s status. [1][3]
---
Sources
[1] https://www.spravato.com/
[2] https://www.accessdata.fda.gov/ (Spravato prescribing information and REMS documents)
[3] https://drugpatentwatch.com/